Safety of administration of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, before curative-intent treatment in patients with HPV16+ oropharyngeal squamous cell carcinoma.Sidharth V. Puram, Douglas R. Adkins, Nikhil Ram-Mohan et al.|Journal of Clinical Oncology|2025Cited by 4
Patient‐Reported Swallowing Outcomes in HPV+ Oropharyngeal Cancer by Postoperative Chemoradiation Dose in MINT and E3311Theresa Tharakan, Ryan S. Jackson, Sidharth V. Puram et al.|Otolaryngology|2025Cited by 2
Characterization of dynamic changes in tumor-infiltrating lymphocytes (TIL) after neoadjuvant administration of CUE-101, an HPV16 E7-HLA-IL2 fusion protein, to patients with HPV+ locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC).Jesse M. Zaretsky, Sidharth V. Puram, Anish Suri et al.|Journal of Clinical Oncology|2025Cited by 0
Abstract CT241: Phase 2 window of opportunity trial of pyrimethamine in locoregionally advanced head and neck squamous cell carcinomaPaul Zolkind, Michael B. Major, Emily Wilkerson et al.|Cancer Research|2026Cited by 0